The World May be Closer to Better Treatments for Parkinson’s Disease

Nearly 10 million people struggle with Parkinson’s disease at the moment.While there is no cure for Parkinson’s disease just yet, treatments such as L-dopa, or Levodopa can help control the symptoms, including stiffness, weakness, and rigidity. Unfortunately, even long-term exposure to L-dopa can cause issues, such as dyskinesia, which can include rapid, involuntary, and uncontrollable movements. However, there may be a solution for levodopa-induced dyskinesia in patients with Parkinson’s disease (LID-PD). In fact, PharmaTher (CSE:PHRM) (OTC:PHRRF) just announced that the U.S. FDA just approved the Company’s Investigational New Drug application to proceed with a Phase 2 clinical trial to evaluate the safety, efficacy and pharmacokinetics of ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease.

Success could also open the door for other psychedelic companies, too, including Mind Medicine Inc. (NEO:MMED)(NASDAQ:MNMD), Compass Pathways (NASDAQ:CMPS), Seelos Therapeutics Inc. (NASDAQ:SEEL), and Cybin Inc. (NEO:CYBN)(OTC:CLXPF).

PharmaTher Announced FDA Approval Read more

TSX Gains Take some of the Sting out of Weekly Losses

Equities in Canada’s largest sector got bruised on the week, but Friday’s gains eased some of the blow, as energy and gold stocks staged impressive rallies.

The TSX rumbled ahead 229.48 points, or 1.2%, to close Friday at 19,365.29. However, the index fell short on the week by 107 points, or 0.55%

The Canadian dollar gained 0.37 cents at 82.54 cents U.S.

Energy stocks were the big winners on the day, with MEG Energy towering 53 cents, or 7.8%, to $7.29, while Vermilion Energy gained 37 cents, or 4.1%, to $9.36.

Among gold plays, Kinross Gold hiked 28 cents, or 3.1%, to $9.41, while Seabridge Gold tacked on 73 cents, or 3.5%, to $21.91.

In health-care Aurinia Pharmaceuticals rose $1.07, or 8%, to $14.42, while Canopy Growth added 85 cents, or 3.2%, to $27.76.

On the economic platform, manufacturing sales bounced back in March, rising 3.5% to $57.8 billion, following … Read more